Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-dose, Two-treatment, Two-sequence, Two-period, Two Way Crossover Bioequivalence Study of Bosiqing Aripiprazole Orally Disintegrating Tablets and ABILIFY Under Fasting/Fed Condition

NCT03232710 is registered in ClinicalTrials.gov with Chengdu Kanghong Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT03232710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03232710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-dose, Two-treatment, Two-sequence, Two-period, Two Way Crossover Bioequivalence Study of Bosiqing Aripiprazole Orally Disintegrating Tablets and ABILIFY Under Fasting/Fed Condition
Lead sponsor
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
June 26, 2017
Completion date
June 30, 2018
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence